The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
Yang MengNadine HertelJohn EllisEdith MoraisHelen JohnsonZoe PhilipsNeil RoskellAndrew WalkerDawn LeePublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2018)
Nivolumab is a cost-effective treatment for advanced melanoma patients in England.